ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Pfizer is likely to show GSK significant competition
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Subscribe To Our Newsletter & Stay Updated
